X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The intend to use the net proceeds from the offering for the commercialization of Jelmyto (mitomycin). It is indicated for the treatment of low-grade upper tract urothelial cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: Jelmyto
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $101.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 17, 2024
Details:
The intend to use the net proceeds from this offering for the commercialization of Jelmyto (mitomycin). It is indicated for the treatment of low-grade upper tract urothelial cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: Jelmyto
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $107.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 17, 2024
Details:
UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2024
Details:
Jelmyto® (mitomycin) is a FDA approved pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel indicated for primary chemoablative treatment of LG-UTUC in adults.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: Jelmyto
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2024
Details:
UGN-103 (mitomycin) selectively inhibits the synthesis of deoxyribonucleic acid, it is being developed for the treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-103
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
UGN-102 (mitomycin) is a DNA synthesis inhibitor which is currently being evaluated in phase 3 clinical trials for the treatment of low-grade, intermediate-risk non-muscle invasive bladder cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-103
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Medac
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 17, 2024
Details:
UGN-102 (mitomycin) selectively inhibits the synthesis of deoxyribonucleic acid and is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. It is being developed for the treatment of LG-IR-NMIBC.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
The proceeds will be used for non-clinical and clinical development activities for company's product candidates including, UGN-102 (mitomycin), an investigational therapy in development for primary chemoablation of low-grade, non-muscle invasive bladder cancer.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 27, 2023
Details:
UGN-102 (mitomycin) selectively inhibits the synthesis of deoxyribonucleic acid and is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. It is being developed for the treatment of LG-IR-NMIBC.
Lead Product(s): Mitomycin
Therapeutic Area: Oncology Product Name: UGN-102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
